Drugs / VNT-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07169318 | Sep 2025 → Nov 2026 expected | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VNT-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07169318 ↗ |
| Action | Inhibit | “inhibiting oligomerization of the influenza nucleoprotein (NP) and thereby inhibiting viral ribonucleic acid (RNA) synthesis.” NCT07169318 ↗ |
| Route | Oral | “administered orally” NCT07169318 ↗ |